Hepion Pharmaceuticals replaces auditor Grassi with Rosenberg Rich Baker Berman
Bitget2026/09/28 10:31- Hepion Pharmaceuticals dismissed auditor Grassi & Co. effective Sept. 22, 2026.
- Rosenberg Rich Baker Berman hired to audit 2026 consolidated financial statements.
- Prior audit reports included a going-concern warning tied to significant operating losses and negative operating cash flow since inception.
- Company reported no accounting or audit-scope disputes with Grassi for 2024-2025 or through Sept. 21, 2026.
- Material weaknesses in internal control over financial reporting were disclosed in recent filings, cited as the only reportable events.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
10-Yr Benchmark Govt Yields - Germany vs Other Nations
Current Spread in Yield Basis Points Germany 3.475 % Australia 5.347 % 187.2 Belgium 4.339 % 86.4 Canada 3.944 % 46.9 Denmark 3.268 % -20.7 France 4.866 % 139.1 Italy 4.604 % 113.0 Japan 3.100 % -37.5 Netherlands 3.577 % 10.2 Spain 4.087 % 61.2 Sweden 3.146 % -32.9 U.K. 5.369 % 189.4 U.S. 5.267 % 179.2 Source: Tullett Prebon via FactSet (END) Dow Jones Newswires October 04, 2026 21:10 ET (01:10 GMT)
‘Ethereum risks being left behind’ – Analysts debate L1’s role in tokenization boom
